IP Library › Granted Patent US 11,969,534
Granted Patent B2
US 11,969,534 · App. 18/143,733 · Granted Apr 30, 2024

Blood treatment device priming devices, methods, and systems

Inventors: James M. Brugger (Newburyport, MA); David Desouza (Essex, MA)
Assignee: NxStage Medical, Inc.
A61M1/3643A61M1/3629A61M1/3644A61M1/3646A61M1/3652A61M1/3672A61M39/10A61M2205/3331A61M2205/702A61M2205/705A61M2205/707
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,969,534
App. No.
18/143,733
Granted
Apr 30, 2024
Kind
B2
Abstract

Simple-to-use systems, methods, and devices for priming replacement blood treatment devices, for swapping the blood treatment devices out, for replacing swapped-out blood treatment devices, and other related operations are described. In embodiments, a blood treatment device can be primed while a therapy is still running. When the replacement blood treatment device is needed, the therapy can be stopped momentarily (less than a minute) for the rapid and safe swap of the blood treatment device. Blood loss can be minimized. The down time from therapy can be minimized.

Claims (17)

1. A method of performing a blood treatment without an anticoagulant, comprising:

initiating an extracorporeal blood treatment employing an initial blood treatment device, the blood treatment employing no anticoagulant;

passing blood through the initial blood treatment device and observing one or more indicators of a blood treatment device-clogging trend;

determining that the initial blood treatment device may need to be replaced responsively to said one or more indicators;

priming a replacement blood treatment device;

determining that the initial blood treatment device should be replaced responsively to said one or more indicators;

replacing the initial blood treatment device with the replacement blood treatment device primed by said priming; and

thereafter, continuing the extracorporeal blood treatment and observing so as to avoid the need for the anticoagulant.

2. The method of claim 1 , wherein the extracorporeal blood treatment occurs over a duration of at least an hour.

3. The method of claim 1 , wherein the initial blood treatment device and the replacement blood treatment device are identical blood treatment devices.

4. The method of claim 1 , wherein the initial blood treatment device and the replacement blood treatment device are dialyzers.

5. The method of claim 1 , wherein the initial blood treatment device and the replacement blood treatment device are micro tubular fiber blood treatment devices.

6. The method of claim 1 , wherein the priming the replacement blood treatment device is performed conditionally based on a result of the determining that the initial blood treatment device may need to be replaced.

7. The method of claim 1 , wherein the one or more indicators includes a signal indicating pressure of blood in a blood line.

8. The method of claim 1 , wherein the one or more indicators includes a signal indicating pressure change of blood in a blood line or other blood circuit element.

9. The method of claim 1 , wherein the one or more indicators includes a signal indicating a flow rate of blood in a blood line.

10. The method of claim 1 , wherein the one or more indicators includes a signal indicating leakage of blood from a blood circuit.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2023
From: BRUGGER, JAMES M.; DESOUZA, DAVID
To: NXSTAGE MEDICAL, INC.
Reel/Frame 063549/0856 →
Continuity (6)
Continuation 17218860 · Mar 31, 2021
Division 16366714 · Mar 27, 2019
Division 15564719
Provisional Application 62298620 · Feb 23, 2016
Provisional Application 62143880 · Apr 7, 2015
Related Publication 20230302212A1 · Sep 28, 2023